Home > Insider Trading > Filing (0001209191-16-100263)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510580	Kite Pharma Inc.	KITE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1610823	Jeffrey Wiezorek	C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404	Svp Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-02-16	9,000	$6.89	22,742	No	4	M	Direct
Common Stock	Disposition	2016-02-16	7,612	$44.00	15,130	No	4	S	Direct
Common Stock	Disposition	2016-02-16	1,388	$44.47	13,742	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2015-11-30	25,000	$0.00	25,000	$6.89
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2016-02-16	9,000	$0.00	9,000	$6.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
25,000	2015-11-30	2024-06-05	No	4	A	Direct
16,000	2015-11-30	2024-06-05	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.37 to $44.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
On June 6, 2014, the reporting person was granted an option to purchase 25,000 shares of common stock, with vesting based exclusively on the Issuer's satisfaction of certain performance criteria. On November 30, 2015, the performance criteria was met, resulting in the full vesting of the option.